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Summary: The effect on blood pressure 
of high (400 mg/day-S400) and moder- 
ate dose (200 mg/day-S200) spirono- 
lactone and chlorthalidone (1 00 mg/day 
-ClOO), given in a random double-blind 
manner was related to plasma renin 
activity and plasma volume in 38 essen- 
t ial  hypertensives. 
The fall in pressure from a control of 
154/103 mm Hg was essentially the 
same after four weeks of each drug- 
S400 ABP 24/13 mm, S200 18/9 mm, 
ClOO 17/12 mm (all P < 0.001). 
Twelve of 37 patients (32%) had low 
initial renin, but this appeared as respon- 
sive to the chlorthalidone stimulus as 
that of the normal renin group. The anti- 
hypertensive effect of all regimens was 
unrelated to plasma renin activity. 
Plasma volume was significantly 
lowered at the end of each treatment 
period, but the decline could not be 
correlated with blood pressure effects. 
Patients with initially low plasma volume 
were more likely to respond to S400 
(r=0.545, P < O.Ol), whereas the anti- 
hypertensive effect of the S200 and 
(2100 regimen-s was independent of this 
variable. 
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Low renin essential hypertension (LRH) and its 
response to spironolactone has been the subject 
of several recent studies’ ‘. Should the response 
in the low renin sub-group prove to be as marked 
as some of these reports suggest, then 20-30:;.1, 
of the essential hypertensive population may be 
expected to maintain good blood pressure 
control on SlOO-S200 mgjday. Identification of 
this sub-group with renin estimation under 
strictly controlled conditions would become 
part of the routine hypertensive screen. 
Excess of an unidentified mineralocorticoid 
in low renin hypertension was first postulated 
following observations on the effect of amino- 
glutethimide by Woods et ~ l . ~ ,  and further 
support has come from spironolactone 
studies’ ’. Adlin and colleagues4, Jose et ~ 1 . ~  
and Vaughan et ul.’ have not found a selective 
spironolactone action and alternate explana- 
tions have been sought for low renin hyper- 
tension. Thus an overexpanded plasma volume, 
inappropriately high aldosterone secretion rates 
and impaired adrenergic sensitivity’ have all 
been investigated, while increased aldosterone 
sensitivity6 has also been postulated. 
Recently it was found that the ‘‘low’’ renin 
sub-group may also be unduly responsive to 
the antihypertensive action of hydrochloro- 
thiazide‘. In contrast, in four patients with 
primary aldosteronism”, a favourable blood 
pressure response was obtained to S200 but not 
to hydrochlorothiazide. 
Vaughan et ul.’ find a similar blood pressure 
effect from spironolactone and chlorthalidone, 
in either low or normal renin groups, in a study 
involving use of open label preparations and 
predominantly 200 mg or less spironolactone. 
Previous studies showing a lack of selective 
action in low renin  hypertension'^^ of “high 
dose” spironolactone employed 200 mg/day 
for 12 and 4 weeks respectively. The term “low 
normal” plasma renin activity has been intro- 
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duced by one group4 to demonstrate a selective 
action of S200. This selective effect became 
apparent only when the “low normal” and the 
truly “low” renin groups were collectively 
compared with the blood pressure response of 
the “normal” renin group. 
The antihypertensive effect of chlorthalidone 
was similar to that of moderate and high dose 
spironolactone in the double blind study of 38 
uncomplicated essential hypertensives reported 
here. In this communication the antihyper- 
tensive effect of these regimens on the low and 
normal renin sub-groups is analysed and 
examined in the light of changes in plasma 
volume and weight. 
Patients and Methods 
Thirty-eight essential hypertensives (resting recumbent 
diastolic pressure > 90 mm Hg) agreed to participate in 
this study. Ages ranged from 20 to 59 years and none had 
greater than grade I1 hypertensive retinopathy. Secondary 
causes of hypertension were ruled out by thorough clinical 
examination and laboratory examination. 
Schedule of Tablets, Visits and Tests 
Three drug regimens, spironolactone 300-400 mg/day, 
spironolactone 200 mg/day and chlorthalidone 100 mg/day 
were each given for four weeks. Spironolactone was given 
as 100 mg and chlorthalidone as 50 mg tablets. The high 
dose spironolactone consisted of two weeks 300 mg/day 
followed by a further two weeks of 400 mg/day. AU anti- 
hypertensive medications and tranqullizers were discon- 
tinued at least four weeks and oral contraceptives six 
months prior to the first visit. Placebo periods of at least 
two weeks preceded each drug. 
Clinic visits and serum electrolyte estimations were 
spaced at two weekly intervals. Placebo tablets were given 
as 2, 3, and 4 tablets per day to correspond with the active 
drug schedules. Random tablet counts on at least one 
occasion in each patient showed better than 95% adherence. 
Randomization and Double-blind Procedure 
Drug and placebo administration were randomized using a 
classical 6 x 6 Latin square method. The patients and the 
clinic nurse taking blood pressure were unaware of the 
tablet schedules or timing of plasma volume determinations. 
Blood Pressure Measurement 
Office blood pressures were taken at the same time of day, 
in the lying position after 15 minutes rest. The average was 
obtained of three readings over five minutes. Phase V 
Korotkoff sounds was taken as the diastolic end point and 
mean BP was derived as diastolic plus 1/3 pulse pressure. 
Individual drug effects were assessed using the immediate 
preceding placebo BP as control. Randomization of the 
study population resulted in placebo blood pressure before 
each drug treatment being similar for the group as a whole. 
Plasma Volume 
Plasma volume was measured after the initial placebo 
period and at the end of each four weeks drug treatment. 
The estimation was performed in the morning, fasting, 
after thirty minutes recumbency. Evans’ blue dye, exactly 
5 ml of a 0.5% solution, was injected and flushed with 
5-10 ml normal saline. Optical density in samples taken 
10, 15 and 20 minutes later from the other arm, without 
venous congestion, was extrapolated to zero time. Previous 
results from this laboratory“ show that this estimation is 
reproducible within close limits over a period of several 
weeks. Plasma volume has been expressed both as ml/cm 
height and as ml/kg weight. 
Plasma Renin Activity 
Plasma renin activity was measured according to the 
method of Haber et al.” by Radioimmunoassay of the 
angiotensin I generated after plasma incubation. The initial 
(PRA’) sample was drawn after two weeks on placebo, 
with salt restriction (100 rneq sodium/day) during the 
second week, and after strict two hour ambulation. The 
sample was immediately placed in ice and centrifuged 
within fifteen minutes in a refrigerated centrifuge (4°C). 
The plasma was then frozen and kept in this state until 
analysis. In 20 patients a further PRA sample (PRA’) was 
drawn under similar conditions, but after the patient had 
taken chlorthalidone 100 mg/day for four weeks. Plasma 
renin activity was expressed as ng%/hour and the ratio 
PRA*/PRA’ served as an expression of the rise in renin 
with diuretic therapy. 
Estimations were performed in duplicate with the error 
of duplicate estimations being 4.5% (range 0-1279. 
Recovery rate of a known amount of angiotensin I was 
116%. In this laboratory, with the preparation described, 
a level for PRA’ of less than 50 ng%/hour falls more than 
2 SD below the mean of a group of normals similarly 
prepared. Thus, patients below t h s  level are considered as 
having low renin essential hypertension. 
Urinary Aldosterone 
Urinary aldosterone excretion was measured by a double 
isotope dilution method* in a twenty-four hour sample 
collected on the last day of the initial placebo period. 
Completeness of urine collection was checked by relating 
urinary creatinine to body mass. 
Statistical Methods 
T-test for paired T-test statistics, student’s T-test for 
comparison of two groups and correlations were performed 
using the CONSTAT computer program of the Statistical 
Research Laboratory at  the University of Michigan. 
Results 
The ages of patients ranged from 20 to 59 years 
(mean 43) and the sex distribution was 27 males, 
11 females. Twenty-six patients were white, ten 
black and two oriental. 
Blood Pressure Effects 
The placebo blood pressure (mean of three 
placebo periods) of the study population was 
154/103 (SDf16/9) mm Hg. Twenty of the 
patients had placebo diastolic pressure over 100 
mm while six fell in the range 90-95 mm. The 
‘Searle Reference Labs. Columbus. Otuo 
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FIGURE 1. A. Distribution of plasma renin activity in 
34 patients in this study. Three with low 
PRA and inadequate salt restriction have 
been excluded. 
6. Urinary aldosterone excretion of pa- 
tients illustrated in A. 
three drug regimens, spironolactone 400 mgl 
day, 200 mg/day and chlorthalidone 100 mgjday 
had each significantly lowered (P < 0.001) 
systolic and diastolic pressure at the end of two 
weeks (Table 1). Chlorthalidone had elicited its 
full blood pressure effect by two weeks whereas 
with the spironolactone regimens further falls 
in pressure followed (Table 1). 
The fall in pressure resulting from four weeks' 
treatment was not significantly different for the 
three regimens, being S400 24/13 mm, S200 
18/9 mm and ClOO 17/12 mm (Table 1). How- 
ever, there was no correlation between the 
antihypertensive effect of the different drugs 
and response to one did not necessarily indicate 
the likelihood of response to another. Normo- 
tension (diastolic < 90 mm) was achieved in 21 
patients with the high dose spironolactone, in 
11 on moderate dose spironolactone and in 12 
with chlorthalidone. 
Initial diastolic pressure was linearly related 
to the fall in blood pressure resulting from S 2 0 0  
and C100. (S200, Y -- 0,4403, P < 0.02, C100, 
r -- 0.3804, P < 0.05).  No such relation existed 
for S400, but subdivision of cases into three 
groups on the basis of placebo diastolic pressure 
(<  100, 100-110, > 110) revealed a greater 
effect of S400 ( P  < 0.05) on the highest in 
comparison with the lowest pressure group. 
The effect of all three drugs though was essen- 
tially similar in any one of these sub-groups. 
Plasma Renin Activity: 
Twelve of thirty-seven patients (32%) had low 
(< 50 ngxihour) plasma renin activity (PRA') 
with satisfactory adherence to salt restriction 
(Table 2). The average twenty-four hour urinary 
sodium of this group was 127 meq (range 88- 
157). Three patients who had low plasma renin 
activity but excreted > 180 meq Na+/day were 
excluded from the renin analyses because such 
high sodium excretion may indicate an in- 
adequate stimulus to renin secretion. At such 
high levels of urine sodium excretion it can 
become impossible to separate normal from 
low renin patients as is well illustrated in the 
nomograms constructed by Laragh's group', 
- TABLE 1 
Blood Pressures after Two and Four Weeks' Treatment. 
~ Spironolactone 400 mg ' Spironolactone 200 rng Chlorthalidone 100 mg 
I (S200) I (ClOOj I (S400j i 
------i- 




I 143197 i- 312 139194 312 
1 
139196 & 4/2 





I 134192 k 412 137/95 k 3/2 1 137193 k 212 
I -24113 k 312: I - 18,'s + 3/21 17/12 f 2/23 
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FIGURE 2. Change in mean blood pressure resulting 
from four weeks of treatment in patients grouped accord- 
ing to initial (low or normal) PRA levels. 
which relate renin activity to urinary Na’ 
excretion. In one patient PRA was not 
measured. Figure 1A shows the distribution of 
plasma renin activity in the low and normal 
renin groups, while Figure 1B illustrates the 
24 hour urinary aldosterone excretion in the 
same groups. The aldosterone excretion in 
normal and low renin groups was similar. 
The decrease in pressure induced by each 
drug was highly significant ( P  < 0.001) (Fig. 
2), irrespective of whether renin was low or 
normal. The antihypertensive effect of any of 
the thrqe drugs failed to correlate with renin 
levels. The action of 5400 in the low renin group 
was greater than that of S200 ( P  < 0.02) (Fig. 
2). However, the effect of S200 in the low renin 
sub-group was indistinguishable from that of 
c100. 
No correlation was found between renin 
levels and initial plasma volume or changes in 
plasma volume resulting from treatment, 
Plusmu Renin Activity ajter Chlorthalidone 
(PRA2)  and the ratio of PRA2/PRA‘ 
Plasma renin activity estimation was repeated 
in seven patients with low PRA’ and in thirteen 
with normal PRA’ after four weeks chlorthali- 
done 100 mg/day. (Table 2, Fig. 3). PRA’ was 
invariably higher and while there was con- 
siderable overlap of PRA’ in the two sub- 
groups, on the whole the initially normal PRA’ 
patients had higher PRA’ levels (1314 v. 439 
kd P W ’  
n P W 2  
PRA 
LOW P R A,‘ N 8 H I G H  P R A ’  
FIGURE 3. Baseline (PRA’) and chlorthalidone stimu- 
lated (PRA2) plasma renin activity in groups subdivided 
on basis of initial PRA level. Broken line indicates lower 
level of normal (50 ng%/hr) PRA’. 
ng%/hour, P < 0-02). However, the percentage 
rise in the low renin patients was fourfold 
greater. Of the eight whose renin response to 
diuretic therapy was “most sensitive” (Table 
2), all but one (No. 19) belonged to the initially 
low renin group. 
Urinary Aldosterone Excretion 
Urinary aldosterone and plasma renin activity 
were linearly related (no ~ 30, r ~ 0.6049, P < 
0 -OOl) ,  while both showed an inverse relation- 
ship to urinary sodium excretion (urinary aldo. 
n - 30, r : -0.4801, P < 0.01; PRA’ n 
35, r -= -0.4125, P < 0.05). The six patients 
with high (> 20 pg/24 hr) urinary aldosterone 
had a more marked diastolic pressure response 
to S400 than those where this variable was 
normal (24 v. 10 mm, P < 0.01). A similar 
pattern was seen with CIOO, but not with S200. 
The aldosterone excretion rate bore no relation- 
ship to the untreated blood pressure. 
Plasma Volume and Weight 
Control plasma volume was 18 * 2 +_ 0.58 ml/cm 
height for males and 16.1 f 0 . 7 7  for females 
(P < 0.05). The value, irrespective of sex was 
17.77 f 0.49 mlicm ht (Table 3). This derivative 
correlates well with plasma volume expressed 
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32 I 95 
as a function of weight (n :- 29, r : 0.6779, 
P < 0.001). The plasma volume (mllcm) was 
found to be identical in males subdivided on the 
basis of control diastolic pressure (cut point 
105 mm Hg). 
Significant weight loss and decrease in plasma 
volume occurred with each four weeks' treat- 
ment (Table 3). However, weight loss bore no 
relationship to change in plasma volume or to 
blood pressure alterations. The drop in weight 
, 90 8 .7  
2.3 I 213 
35 8 .3  1 18.4 
i 
j 
resulting from any of the three treatments was 
not influenced by initial plasma renin activity. 
A greater decline in pressure was found in the 
low plasma volume group (upper and lower 
tertiles compared P < 0.01) on high dose 
spironolactone. There was no such difference 
in the effect of the two other regimens. There 
was a negative correlation between initial 
plasma volume and fall in mean blood pressure 
on S400 (n - -  29. r -0.545, P < 0.01). 
~~ 
TABLE 2 
Plasma Renin Letels in control period (PRA'), after 4 weeks Chlorthalidone 100 mgiday (PRA') and ratio of PRAZ/PRA'. 
as well a$ urinary sodium and aldosterone excretion at the time of PRA' sampling 
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TABLE 3 
Plasma Volume (PV) and Weight (Wt.) (k SEM): Changes (A) with four neeks treatment 
- ~ _ _ _ _ _  - 
I 
Control S400 s200 Cl00 
Plusmu Volume APV APV APV 
- I  75+0 53t ml cm ht 17 77+0 49 ’ 1 53+0 54* -2 05+0 46f 
mltkg wt 78  4 2 k 1  42 , 3 52k1  22* 4 5 3 + l  02$ ~ 4 I lk1  24t 
~- --- _ _ _ _ _ _ _  __ - - -  ~ 
I 
i 
ml 299Sk104 ; 260*95* 352&-80 2fi 296+91 3t  
S400, 5200. ClOO notation as before : p < o  001 t -  p<O 01 * -  p < 0  02 
whereas the pressure effect of the S200 and ClO0 
regimens was independent of this variable. The 
decrease in plasma volume resulting from the 
three regimens was not correlated with their 
antihypertensive effect. 
Serum Potassium and Sodium 
The mean untreated serum potassium of the 
thirty-eight patients was 4.0 i 0.09 mEq/l. Four 
weeks’ treatment with each diuretic caused the 
following changes : 
Chlorthalidone 100 mg/day, 4.1 to 3.0 mEq/l 
( P  < 0.001). 
Spironolactone 400 mgiday, 4 .0  to 4 .3  mEq/l 
(P < 0.01). 
Spironolactone 200 mglday, 4 .0  to 4 .2  mEqll 
(n. s .). 
A small fall in serum sodium occurred with 
each treatment but this was not significant; e.g. 
chlorthalidone 100 mg/day caused control level 
of 140 i 0.54 to fall to 118 k 0.27 mEq/l. 
Discussion 
A similar antihypertensive effect has been noted 
in 38 uncomplicated essential hypertensives 
when given high (300-400 mg/day) and moderate 
(200 mgjday) doses of spironolactone* for four 
weeks. The effect of chlorthalidone 100 mgiday 
was comparable, although its action is indepen- 
‘Alducionr A was first investigated in 1961’’ Prior tn that time the Aldactone 
available was roughly one fourth as potent The name Aldactone A was changed 
to Aldactone in 1965-66. so that the currently available Aldactnne ir 4 > more 
potent than the preparation of the same name available in the late fifties and 
early sixties. 
dent of mineralocorticoid antagonism. Sub- 
division of patients on the basis of initial plasma 
renin activity (PRA’) or diuretic stimulated 
renin (PRA’) failed to indicate a pattern of 
blood pressure response which could be related 
to these parameters on any of the three treat- 
ments. The low renin sub-group did not show 
a greater response to high dose spironolactone 
and chlorthalidone was as effective. 
The separation of a portion of essential 
hypertensives into a low renin category may be 
artificial and it’s quite possible that we are 
merely looking at the lower end of a normal 
distribution. Thus, a clear distinction of response 
to treatments would not necessarily be expected 
on the basis of renin levels and even if such a 
distinction were found it would not have to 
imply the existence of a distinct entity of “low 
renin essential hypertension”. Nor indeed 
would it favour the postulate of excessive 
mineralocorticoid activity unless the response 
was confined to a specific mineralocorticoid 
antagonist. 
The similarity of response of the low renin 
group to spironolactone and chlorthalidone 
does not contradict the postulate of excessive 
mineralocorticoid being responsible for the 
renin suppression. It is possible that mineralo- 
corticoid inhibition, as with spironolactone or 
the facilitation of sodium excretion with 
chlorthalidone can have similar effects on 
blood pressure and plasma volume. 
The observed lack of correlation between the 
antihypertensive effects of S400 and Cl00 is 
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hard to explain as their net BP effect on the 
group as a whole is similar. and presumably 
they have a common final path of action 
through salt and water excretion. The effect of 
s200 in the low renin group is significantly less 
than that of S400, but rather than illustrating 
a selective action of S400 in low renin hyper- 
tension, the result could indicate a relative lack 
of response to S200. The high dose and duration 
of spironolactone treatment used in this study 
was comparable to other regimens in the recent 
literature’ 4.6. 
The results of Jose, Crout and Kaplan6 agree 
with the finding in this paper in showing a 
uniform antihypertensive effect from spirono- 
lactone in normal and low renin sub-groups. 
While their doses have been criticised as 
inadequate to achieve total blockade in 
situations of increased mineralocorticoid secre- 
tion, Gwinup and Steinberg’’ have noted 
marked BP responses to the same dose of 
spironolactone in proven mineralocorticoid 
hypertension. The more recent studies of 
Vaughan et al.’ have also found a lack of 
selective spironolactone action in low renin 
hypertension, with the demonstration that 
chlorthalidone has a similar antihypertensive 
effect. The dose of spironolactone in that study 
was variable (50-400 mg) with the most common 
dose being 200 mg/day or less, administered as 
an open label preparation. Nearly 40x of low 
renin hypertensives in the study of Vaughan 
et aL7 were aged above 60 years, whereas only 
three out of 28 of the normal renin groups 
exceeded this age. The work of Adlin et 
indicates that the “low” renin sub-group may 
also be more responsive to hydrochlorothiazide. 
We would have some reservations about the 
interpretation of these results, as a “low” renin 
group has been created by pooling results of 
truly low and “low normal” renin patients. 
Comparison of their truly low renin patients 
with the rest still shows high dose spironalactone 
and hydrochlorothiazide to have comparable 
effects, but the low renin sub-group is no longer 
distinguishable as more responsive. 
Twelve of thirty-seven patients (32%) in this 
study were found to have low plasma renin 
activity, and this figure is in agreement with 
most other series’.2J61 4. However, analysis of 
renin after four weeks of ClOO in the low renin 
patients showed that the renin-angiotensin axis 
was in one respect more responsive, as the 
percentage rise in renin was found to be greater 
than that of the normal PRA group (Table 2). 
These findings raise the important question of 
a standardised renin stimulus” before 
essential hypertensives are labelled as “low 
renin hypertensives“. While Carey’s group’ 
employed frusemide in their preparation, 
others” have shown that added salt restriction 
(10 mEqNa+/Day) further reduced by 15% 
the number falling in the low renin category. 
Crane and colleagues’ demonstrated that with 
repeat testing the number in the low renin 
sub-category progressively declines. 
Several series by showing a marked 
dependence of the antihypertensive properties 
of spironolactone on renin levels, are at variance 
with this study. However, the composition of 
our low renin group, with five white males, four 
black males, two black females and one white 
female is somewhat different to that of Spark 
and Melby’ who in a group of eight low renin 
hypertensives had seven females ofwhom six gave 
a past history of toxaemia of pregnancy. While 
our patients have clearly milder hypertension 
than those in other studies’ ’, the pressures are 
comparable to those of Woodi et ~ 1 . ~ .  Besides, 
the BP effect of S400 observed by Spark and 
Melby’ and Carey et al.’ is considerably in 
excess of that seen when mineralocorticoid 
blockade was achieved by amin~gultethimide~. 
This raises the possibility of an antihypertensive 
effect from S400 in addition to that resulting 
from mineralocorticoid antagonism. Further, 
the effect of SlOO maintenance on subsequent 
BP levels is not uniform1.’. 
Baseline plasma volume in this series corres- 
ponds closely with Tarazi et al‘s2’ figures in 
essential hypertensives and the significantly 
lowered plasma volume at four weeks is in 
keeping with a slow spironolactone effect. The 
finding that the volume effect of chlorthalidone 
in the group as a whole is similar to that of 
spironolactone, could indicate a subset of 
essential hypertensives which is volume sensi- 
tive, responding non-specifically to any alter- 
ation in plasma volume. The lack of correlation 
between the observed plasma volume effects of 
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chlorthalidone and spironolactone is not 
incompatible with the postulate of a volume 
sensitive group, but it does suggest that different 
individuals may respond to the two groups of 
diuretics. It is hard to explain the preferential 
action of high dose spironolactone (S400) on 
the BP of the low plasma volume group in this 
study, but it is not the pattern to be expected 
if S400 were acting on excess of an unidentified 
mineralocorticoid2 None of the three regimens 
showed a correlation between decrease in 
plasma volume and change in blood pressure. 
The significant weight loss with each treatment 
at four weeks bore no relation to alterations 
either in plasma volume or blood pressure and 
this may indicate variation in individual sensi- 
tivity of different patients to diuretics. Further 
studies on the changes in various body fluid 
compartments may offer insights into these 
problems. 
In the light of our findings that S400, S200 
and ClOO have equivalent antihypertensive 
effects on groups of uncomplicated essential 
hypertensives subdivided on the basis of plasma 
renin activity, it would be hard to recommend 
routine screening of essential hypertensives for 
plasma renin activity for possible therapeutic 
benefit. The work of Adlin et al.4 and Vaughan 
et u I .~ ,  while showing a heightened BP response 
to spironolactone in low renin hypertension 
agrees with our findings in demonstrating a 
similar effect from thiazide type diuretics. 
In this study, the dynamic response of the 
renin-angiotensin axis and plasma volume to 
diuretics appears no less in low renin hyper- 
tension than in normal renin essential hyper- 
tensives. We have also confirmed that 
spironolactone does not necessarily have a 
“specific” BP effect in low renin hypertensives 
as its antihypertensive action in high doses in 
low and normal renin sub-groups resembled 
that of chlorthalidone. This finding is supported 
by recent evidence on the similarity of effect of 
spironolactone and amiloride on the blood 
pressure and metabolic parameters of cases of 
aldosterone secreting adenomas22. 
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